Yantai Dongcheng Pharmaceutical's (SHE:002675) unit, Yantai Lannacheng Biotechnology, obtained approval from China's National Medical Products Administration for the clinical trial of 177Lu-LNC1009 Injection, according to a Shenzhen bourse disclosure on Monday.
The drug is used to treat patients with advanced malignant solid tumors expressing fibroblast activation protein and integrin αvβ3.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments